Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Antibody-Drug Conjugate Achieves High Response Rates as Frontline Treatment in Aggressive, Rare Blood Cancer

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

February 11, 2026


February 13 2026

February 12 2026

February 11 2026

February 10 2026

February 9 2026

February 8 2026

February 7 2026

February 6 2026

February 5 2026

February 4 2026

February 3 2026

February 2 2026

February 1 2026

January 31 2026

January 30 2026